Niraparib-d5
Niraparib-d5 (MK-4827-d5) is the deuterium labeled Niraparib (HY-10619) . Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity[1][2][3].
Product Specifications
Product Name Alternative
MK-4827-d5
UNSPSC
12352005
Target
Apoptosis; Isotope-Labeled Compounds; PARP
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Others
Field of Research
Cancer
Smiles
O=C(N)C1=CC=CC2=C(N(N=C12)C3=CC=C(C=C3)[C@H]4C([2H])(NC([2H])(CC4)[2H])[2H])[2H]
Molecular Formula
C19H15D5N4O
Molecular Weight
325.42
References & Citations
[1]Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375 (22) :2154-2164.|[2]Wang L, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30 (6) :2113-20.|[3]Bridges KA, et al. Niraparib (MK-4827), a novel poly (ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5 (13) :5076-86.|[4]Jones P, et al. Discovery of 2-{4-[ (3S) -piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827) : a novel oral poly (ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52 (22) :7170-85.
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-W759435/
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
